Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

JAKAFI

RUXOLITINIB PHOSPHATE

Standard Dose
EQ 10MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview JAKAFI is listed in Drugs@FDA under application 202192 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient RUXOLITINIB PHOSPHATE Form and strength TABLET;ORAL - EQ 10MG BASE Sponsor INCYTE CORP Submission history Latest submission status date: 2023-01-31 00:00:00.

Structured Monograph

Clinical summary

Approval overview JAKAFI is listed in Drugs@FDA under application 202192 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient RUXOLITINIB PHOSPHATE Form and strength TABLET;ORAL - EQ 10MG BASE Sponsor INCYTE CORP Submission history Latest submission status date: 2023-01-31 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.